drugset / Trial / NCT00887575

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

NCT00887575

Phase 1/2 Completed 54 enrolled SCRI Development Innovations, LLC Pfizer · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial will examine the combination of sunitinib plus paclitaxel and carboplatin as neoadjuvant treatment for locally advanced breast cancer.

Timeline

Start
2009-06
Primary completion
2013-07
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule Intravenous
Subject Paclitaxel Small molecule 70 mg/m2 Intravenous
Subject Paclitaxel Small molecule 80 mg/m2 Intravenous
Subject Sunitinib Small molecule 25 mg Oral
Subject Sunitinib Small molecule 37.5 mg Oral

Indications